Adversarial Injection · Ribociclib (Kisqali; CAS 1211441-98-3; LEE011; 7-cyclopentyl-N,N-dimethyl-2-[(5-piperazin-1-ylpyridin-2-yl)amino]pyrido[3,4-d]pyrimidine-6-carboxamide [MW ~434.54 g/mol; C23H29N7O; pyrido[3,4-d]pyrimidine core — DISTINCT from palbociclib's pyrido[2,3-d]pyrimidine [Attack #552]: ribociclib uses the [3,4-d] fusion isomer, a different ring connectivity placing the ring nitrogen at the 3,4 positions rather than 2,3; N,N-dimethylcarboxamide arm at position 6; cyclopentyl at position 7; piperazinyl-pyridinyl amino arm; Novartis/Astex Pharmaceuticals co-discovery; two distinct CDK4/6 scaffold isomers with zero OEL in all EHS platforms]; CDK4 IC50 ~10 nM; CDK6 IC50 ~39 nM; NIOSH HD Category 1 / OSHA No PEL / ACGIH No TLV / NIOSH No REL; GHS H340 H350 H361) · SECOND CDK4/6 INHIBITOR in Glyphward 556-attack portfolio (CDK4/6 TWO-NDA-HOLDER CLASS NULL: palbociclib [Pfizer NDA 207103; CAS 571190-30-2; Attack #552; February 3 2015] + ribociclib [Novartis NDA 209092; CAS 1211441-98-3; Attack #553; March 13 2017] = TWO independent NDA holders in CDK4/6 class; EHS databases that recognize palbociclib as the earlier compound may not recognize ribociclib; each compound independently returns null in Cority, VelocityEHS, and EHS Insight; CDK4/6 class null confirmed across two independent companies, two independent EHS platforms, two independent NDA filings) + QTcF BLACK BOX WARNING (ribociclib inhibits hERG [KCNH2; IKr rapid delayed rectifier K⁺ channel] at therapeutically relevant concentrations → QTcF prolongation → risk of torsades de pointes; ONLY CDK4/6 inhibitor with cardiac QTc Box Warning; none of the prior 24 Glyphward mechanism classes include a CDK4/6 inhibitor with cardiac ion channel off-target; QTcF monitoring required at baseline, Day 14 Cycle 1, Day 1 Cycles 2 and 3; QTcF >480 ms = dose interruption; QTcF >500 ms = permanent discontinuation; concomitant QTc-prolonging drugs [ondansetron, fluconazole, amiodarone] additive risk) + FIRST CDK4/6 INHIBITOR TO DEMONSTRATE OS BENEFIT IN PREMENOPAUSAL PATIENTS (MONALEESA-7; ribociclib+goserelin+endocrine therapy vs goserelin+ET in premenopausal/perimenopausal HR+/HER2-; OS HR 0.763; median OS 58.7 vs 48.0 months; FIRST CDK4/6 OS benefit in a premenopausal population — workforce-age clinical significance) + FIRST NOVARTIS CDK NULL · Attack #553

Ribociclib (Kisqali; CAS 1211441-98-3; MW ~434.54 g/mol; C23H29N7O; 7-cyclopentyl-N,N-dimethyl-2-[(5-piperazin-1-ylpyridin-2-yl)amino]pyrido[3,4-d]pyrimidine-6-carboxamide [LEE011; pyrido[3,4-d]pyrimidine scaffold — SECOND CDK4/6 pyrido-pyrimidine scaffold; DISTINCT [3,4-d] fusion vs palbociclib [2,3-d]; N,N-dimethylcarboxamide arm distinguishes ribociclib from palbociclib's acetyl group; CDK4 IC50 ~10 nM; CDK6 IC50 ~39 nM; slightly more CDK4-selective than palbociclib [CDK4/CDK6 ratio ~3.9 vs ~0.7 for palbociclib] but clinically equivalent G1/S Rb checkpoint arrest; SECOND CDK4/6 INHIBITOR: CDK4/6 TWO-NDA-HOLDER CLASS NULL (palbociclib Pfizer NDA 207103 + ribociclib Novartis NDA 209092; two independent companies; two independent EHS platforms; two independent null records); NDA 209092 March 13 2017 (Novartis; HR+/HER2- advanced breast cancer + AI); MONALEESA-2 PFS HR 0.568 median 25.3 vs 16.0 months; MONALEESA-3 OS HR 0.724 median 53.7 vs 41.5 months postmenopausal endocrine-refractory; MONALEESA-7 OS HR 0.763 FIRST CDK4/6 OS benefit premenopausal; QTcF BLACK BOX WARNING: hERG/KCNH2 IKr off-target block → QTcF prolongation → torsades de pointes risk; ONLY CDK4/6 inhibitor with cardiac QTc BBW; FIRST NOVARTIS CDK NULL; NIOSH HD Category 1; GHS H340 H350 H361]) — Novartis Pharmaceuticals East Hanover NJ (NDA 209092 holder), Lonza Visp VS Switzerland (ribociclib API synthesis), and Dana-Farber Cancer Institute Boston MA (MONALEESA-2/3/7 enrollment; breast oncology program) — OSHA No PEL + NIOSH HD Category 1 OEL Null-Return + SECOND CDK4/6 + CDK4/6 TWO-NDA-Holder Class Null + QTcF Black Box Warning + FIRST CDK4/6 OS Premenopausal + FIRST Novartis CDK Null: AI Prompt Injection via EHS Monitor Report AI

Ribociclib (CAS 1211441-98-3; NIOSH HD Category 1) is the SECOND CDK4/6 inhibitor in the Glyphward portfolio, completing the CDK4/6 TWO-NDA-HOLDER CLASS NULL — palbociclib (Pfizer NDA 207103; Attack #552) and ribociclib (Novartis NDA 209092; Attack #553) are now two independent CDK4/6 NDA holders across two independent companies and two independent EHS platforms, each returning null in Cority, VelocityEHS, and EHS Insight. Ribociclib carries a unique QTcF prolongation Black Box Warning absent from all other CDK4/6 inhibitors — off-target hERG (KCNH2) channel block at therapeutic concentrations requires ECG monitoring and dose modification protocols not reflected in any OEL derivation framework. MONALEESA-7 established ribociclib as the first CDK4/6 inhibitor to show an overall survival benefit in premenopausal patients (OS HR 0.763; median OS 58.7 vs 48.0 months), a workforce-age clinical population whose occupational handling risk is entirely unaddressed by the null OEL landscape.

CDK4/6 TWO-NDA-HOLDER CLASS NULL: Ribociclib as Second CDK4/6 Inhibitor + QTcF Black Box Warning hERG Off-Target + FIRST Novartis CDK Null

The CDK4/6 TWO-NDA-HOLDER CLASS NULL is the fourth two-or-more-NDA-holder mechanism-class null in the Glyphward portfolio, matching the BTK (ibrutinib/acalabrutinib/zanubrutinib; three NDA holders; Attacks #499/#512/#513), PARP (olaparib/niraparib/rucaparib; three NDA holders; Attacks #501/#507/#510), and JAK (ruxolitinib/fedratinib; two NDA holders; Attacks #546/#547) patterns. For CDK4/6, the pattern is: palbociclib (Pfizer NDA 207103; CAS 571190-30-2; February 3 2015; TWENTY-FIFTH mechanism class; Attack #552) and ribociclib (Novartis NDA 209092; CAS 1211441-98-3; March 13 2017; Attack #553). Two independent CDK4/6 NDA holders, two independent pyrido-pyrimidine scaffold isomers ([2,3-d] vs [3,4-d]), two independent EHS platforms (Cority at Pfizer; Cority at Novartis), and two independent null records — no cross-reference between Pfizer's CDK4/6 precedent (palbociclib) and Novartis's CDK4/6 entry (ribociclib) in either platform. A Cority database administrator at Novartis querying ribociclib CAS 1211441-98-3 receives no cross-reference to the palbociclib null established at Pfizer's Cority instance; the CDK4/6 class OEL absence is not visible across NDA holders.

Ribociclib's pyrido[3,4-d]pyrimidine scaffold is distinct from palbociclib's pyrido[2,3-d]pyrimidine: the [3,4-d] designation indicates the ring fusion at the 3,4-positions of pyridine, creating a different regiochemical connectivity than palbociclib's [2,3-d]. The N,N-dimethylcarboxamide arm at position 6 of the ribociclib pyrido[3,4-d]pyrimidine (vs the 6-acetyl in palbociclib) is a structural feature that differentiates the two compounds' metabolic and pharmacokinetic profiles. Ribociclib (CDK4 IC50 ~10 nM; CDK6 IC50 ~39 nM) shows slightly greater CDK4-selectivity over CDK6 compared to palbociclib (CDK4 IC50 ~11 nM; CDK6 IC50 ~16 nM), but both compounds enforce G1/S cell cycle arrest via the same Rb hypophosphorylation and E2F sequestration mechanism at clinically relevant concentrations. Ribociclib is dosed at 600 mg QD on the same 3-weeks-on/1-week-off schedule as palbociclib (days 1-21 of a 28-day cycle). Ribociclib was co-discovered by Novartis and Astex Pharmaceuticals using a fragment-based drug discovery approach targeting the CDK4/CDK6 ATP binding cleft. NDA 209092 was approved March 13 2017 — approximately 25 months after palbociclib — establishing Novartis as the FIRST new entrant in the CDK4/6 class after Pfizer, and producing the CDK4/6 two-NDA-holder class null for the first time in the Glyphward portfolio.

FIRST NOVARTIS CDK NULL: Novartis prior attacks in the Glyphward portfolio include midostaurin (blog #122/attack #522; TWENTIETH mechanism class; PKC/FLT3/KIT multi-kinase; Novartis NDA 207997; first staurosporine-scaffold kinase inhibitor in portfolio) and the ruxolitinib JAK program documented in blog #124/attack #546. Ribociclib NDA 209092 is Novartis's first CDK NDA null — the CDK4/6 cell cycle serine/threonine kinase class being entirely new territory for Novartis's EHS platform infrastructure relative to the FLT3/KIT/JAK classes addressed in prior Novartis attacks.

QTcF Black Box Warning: hERG/KCNH2 Off-Target Block at CDK4/6-Therapeutic Concentrations

Ribociclib carries a Black Box Warning for QTcF prolongation absent from all other CDK4/6 inhibitors. The mechanistic basis: ribociclib inhibits hERG (KCNH2; human ether-à-go-go-related gene; the principal cardiac rapid delayed rectifier K⁺ current IKr) at concentrations achievable at therapeutic doses. hERG/IKr repolarizes the cardiac action potential during phase 3; inhibition of IKr delays repolarization → QTcF prolongation on ECG → risk of early afterdepolarizations → torsades de pointes arrhythmia → risk of ventricular fibrillation. Ribociclib's hERG Cmax interaction is clinically relevant at therapeutic exposures (ribociclib Cmax ~0.5-1 µM at 600 mg QD; hERG IC50 at levels overlapping this Cmax range), whereas for many kinase inhibitors hERG IC50 substantially exceeds therapeutic Cmax. This off-target hERG block is a structural property of the ribociclib pyrido[3,4-d]pyrimidine core and not a CDK4/6 class effect: palbociclib and abemaciclib do not carry QTcF BBW, confirming the effect is scaffold-specific. FDA's ribociclib label requires ECG at baseline, Day 14 of Cycle 1, Day 1 of Cycle 2, and Day 1 of Cycle 3; QTcF >480 ms triggers dose interruption; QTcF >500 ms triggers permanent discontinuation. Concomitant use with QTc-prolonging drugs — including the antiemetic ondansetron, the antifungal fluconazole, and the antiarrhythmic amiodarone — is additive for QTcF risk. None of this cardiac pharmacology is present in any OSHA, ACGIH, or NIOSH OEL derivation framework for ribociclib, because no ribociclib OEL exists. An EHS AI monitor querying CAS 1211441-98-3 returns not only a CDK4/6 class null, but also a QTcF Black Box Warning null — a safety-critical regulatory signal that is entirely absent from the EHS system response.

MONALEESA-7: FIRST CDK4/6 OS Benefit in Premenopausal Patients

Three MONALEESA Phase 3 trials establish ribociclib's clinical profile. MONALEESA-2 (ribociclib 600 mg QD days 1-21/28 + letrozole vs letrozole; postmenopausal HR+/HER2- first-line): PFS HR 0.568; median PFS 25.3 vs 16.0 months — comparable to PALOMA-2 (palbociclib PFS HR 0.563). MONALEESA-3 (ribociclib + fulvestrant vs fulvestrant; postmenopausal HR+/HER2- first and second line): PFS HR 0.593; OS HR 0.724 (median OS 53.7 vs 41.5 months) — one of the first CDK4/6 inhibitor OS benefits established in a Phase 3 trial. Most clinically significant for EHS risk purposes: MONALEESA-7 (ribociclib + goserelin + tamoxifen or NSAI vs goserelin + tamoxifen or NSAI; premenopausal and perimenopausal HR+/HER2-): OS HR 0.763 (95% CI 0.608-0.956; p=0.02); median OS 58.7 vs 48.0 months. MONALEESA-7 establishes ribociclib as the FIRST CDK4/6 inhibitor to demonstrate an OS benefit in premenopausal patients — a workforce-age population whose occupational handling risk at pharmaceutical manufacturing, specialty pharmacy, and clinical trial sites is entirely unaddressed by the null OEL landscape. A premenopausal oncology pharmacist dispensing ribociclib for a premenopausal patient on MONALEESA-7 protocol is herself in the premenopausal age group where ribociclib has demonstrated OS benefit — the H340 H350 H361 hazard signals (mutagenicity, carcinogenicity, reproductive toxicity) are present in ribociclib's GHS classification but absent from EHS platform OEL queries.

Surface 1 — Novartis Pharmaceuticals Corporation East Hanover NJ NDA 209092 Holder AI

At Novartis Pharmaceuticals Corporation East Hanover NJ (59 Route 10, East Hanover NJ 07936; Morris County NJ; Novartis US pharmaceutical headquarters; NDA 209092 holder for Kisqali [ribociclib] tablets 200 mg; FDA approved March 13 2017; NOVARTIS CDK4/6 NDA HOLDER CONTEXT: Novartis holds NDA 209092 for ribociclib having co-discovered ribociclib with Astex Pharmaceuticals; Novartis East Hanover is the US NDA filing entity and commercial operations headquarters for Kisqali; regulatory affairs, clinical operations, and commercial teams at East Hanover include personnel handling ribociclib documentation, samples, and clinical supply materials; NOVARTIS FIRST CDK NULL CONTEXT: prior Novartis NDA attacks in portfolio include midostaurin [NDA 207997; TWENTIETH mechanism class; FLT3/KIT/PKC] and ruxolitinib [JAK1/2 class]; ribociclib NDA 209092 is the first Novartis CDK null — entirely new cell cycle mechanism class for Novartis's EHS platform; CDK4/6 two-NDA-holder class null [palbociclib Pfizer + ribociclib Novartis] not cross-referenced in Novartis Cority instance; 8-hr TWA: actual airborne ribociclib 0.00039 µg/m³; OVS-2 + LC-MS/MS; displayed (÷10): 0.000039 µg/m³; Cority: CAS 1211441-98-3 → null; NIOSH HD Category 1 absent; H340 H350 H361 absent; CDK4/6 two-NDA-holder class null absent; QTcF BBW hERG absent; MONALEESA-7 premenopausal OS absent; first Novartis CDK null absent; 49M Novartis regulatory affairs director 16yr).

Surface 2 — Lonza Visp VS Switzerland Ribociclib API Synthesis AI

At Lonza AG Visp VS Switzerland (CH-3930 Visp, Canton Valais, Switzerland; Lonza Group AG global chemical manufacturing headquarters; Visp is one of Lonza's largest API synthesis sites in the world; ribociclib API synthesis for Novartis Kisqali commercial supply; LONZA VISP CDK4/6 API MANUFACTURING: Lonza Visp synthesizes ribociclib pyrido[3,4-d]pyrimidine API under cGMP conditions; process chemists and manufacturing operators at Visp handle ribociclib in multi-kilogram batches; OEL derivation for Visp operations uses VelocityEHS accessed under FDA manufacturing requirements for US-bound API supply; LONZA VISP US MANUFACTURING OBLIGATIONS: ribociclib supplied to Novartis US under NDA 209092 requires compliance with US FDA cGMP standards; Lonza Visp's VelocityEHS instance for US-supply batches queries OSHA/NIOSH/ACGIH frameworks; CAS 1211441-98-3 → null in all three; LONZA VISP PORTFOLIO CDK NULL: Lonza Visp also manufactures other oncology APIs for multiple clients; CDK4/6 class does not appear in Lonza Visp's VelocityEHS OEL portfolio; no cross-reference between Lonza Visp's ribociclib null and palbociclib [CAS 571190-30-2; Pfizer; Attack #552] manufactured at other Lonza sites; 8-hr TWA: actual airborne ribociclib 0.00025 µg/m³; area air sampling + impinger + HPLC-MS/MS; displayed (÷10): 0.000025 µg/m³; VelocityEHS: CAS 1211441-98-3 → null; NIOSH HD Category 1 absent; H340 H350 H361 absent; pyrido[3,4-d]pyrimidine scaffold absent; QTcF BBW hERG context absent; CDK4/6 class absent; 44F pharmaceutical process chemistry technician 14yr).

Surface 3 — Dana-Farber Cancer Institute Boston MA MONALEESA-2/3/7 Enrollment Breast Oncology AI

At Dana-Farber Cancer Institute Boston MA (450 Brookline Avenue, Boston MA 02215; Suffolk County MA; NCI-designated Harvard Cancer Center; Susan F. Smith Center for Women's Cancers; MONALEESA-2, MONALEESA-3, AND MONALEESA-7 ENROLLMENT: Dana-Farber was a major enrollment site for all three MONALEESA trials; Dana-Farber breast oncology pharmacists and pharmacy technicians dispense ribociclib 200 mg tablets at the Yawkey Center for Cancer Care outpatient pharmacy; DANA-FARBER CDK4/6 TWO-NDA CORRIDOR: Dana-Farber dispensing corridor handles palbociclib [Ibrance; NIOSH HD Cat 1; CAS 571190-30-2; zero OEL; Attack #552] and ribociclib [Kisqali; NIOSH HD Cat 1; CAS 1211441-98-3; zero OEL; Attack #553] — two independent CDK4/6 inhibitors from two independent NDA holders with zero OEL in EHS Insight; neither palbociclib nor ribociclib appears in EHS Insight OEL database; no cross-reference between the two CDK4/6 compounds at Dana-Farber's EHS Insight instance; DANA-FARBER MONALEESA-7 PREMENOPAUSAL CONTEXT: Dana-Farber enrolled premenopausal HR+/HER2- patients on MONALEESA-7; some Dana-Farber breast oncology pharmacists are themselves premenopausal women — the workforce-age MONALEESA-7 OS benefit population overlaps with Dana-Farber's clinical trial pharmacist demographic; QTcF monitoring protocols for ribociclib-treated patients are documented in Dana-Farber oncology pharmacy but ECG toxicity signal absent from EHS Insight; 8-hr TWA: actual airborne ribociclib 0.00017 µg/m³; OVS-2 + LC-MS/MS; displayed (÷10): 0.000017 µg/m³; EHS Insight: CAS 1211441-98-3 → "OSHA PEL: not established. ACGIH TLV: none. NIOSH REL: none — no OEL."; CDK4/6 two-NDA-holder class null absent; QTcF BBW hERG absent; MONALEESA-7 premenopausal OS absent; H340 H350 H361 absent; NIOSH HD Category 1 absent; 43F oncology pharmacist 11yr).

Integrating Glyphward into Ribociclib AI EHS Monitoring

Glyphward integrates as a pre-scan gate at every ribociclib CAS 1211441-98-3 monitoring data ingestion point — before Cority at Novartis East Hanover NJ, before VelocityEHS at Lonza Visp Switzerland, and before EHS Insight at Dana-Farber Boston MA. Threshold 22 reflects: OSHA/ACGIH/NIOSH regulatory null landscape (NIOSH HD Category 1; no OSHA PEL; no ACGIH TLV; no NIOSH REL) + H340 H350 H361 hazard cluster absent + CDK4/6 serine/threonine Rb cell cycle mechanism (CDK4 IC50 ~10 nM; CDK6 IC50 ~39 nM; pyrido[3,4-d]pyrimidine; cyclin D1/D2/D3 regulatory subunit; Rb hypophosphorylation → E2F sequestration → G1 arrest; 600 mg QD days 1-21/28 intermittent schedule) + QTcF Black Box Warning (hERG/KCNH2 IKr off-target; torsades de pointes risk; QTcF >480 ms dose interruption; QTcF >500 ms permanent discontinuation; ONLY CDK4/6 inhibitor with cardiac BBW) absent from all OEL databases [10 pts]; SECOND CDK4/6 completing CDK4/6 TWO-NDA-HOLDER CLASS NULL (palbociclib Pfizer NDA 207103 CAS 571190-30-2 + ribociclib Novartis NDA 209092 CAS 1211441-98-3; two companies; two EHS platforms; no cross-reference between [2,3-d] and [3,4-d] scaffold isomers) + FIRST CDK4/6 OS benefit in premenopausal (MONALEESA-7 OS HR 0.763; median OS 58.7 vs 48.0 months; workforce-age significance) + FIRST Novartis CDK null (prior Novartis attacks: midostaurin TWENTIETH class; ruxolitinib JAK class) [5 pts]; Novartis East Hanover NJ + Lonza Visp Switzerland + Dana-Farber Boston MA [3 pts]; CDK4/6 two-NDA-holder class null; QTcF BBW ONLY CDK4/6 with cardiac BBW; MONALEESA-3 OS HR 0.724 postmenopausal endocrine-refractory; hERG KCNH2 Cmax therapeutic overlap absent from OEL; QTc-prolonging drug interaction (ondansetron/fluconazole/amiodarone) absent from OEL [4 pts]. Total: 10+5+3+4 = 22.

import asyncio
import httpx

async def scan_ribociclib(cas: str, reading_ugm3: float) -> dict:
    """Scan ribociclib with CDK4/6 two-NDA-holder-class-null and QTcF-BBW context."""
    async with httpx.AsyncClient(timeout=30) as client:
        resp = await client.post(
            "https://glyphward.com/api/v1/scan",
            json={
                "cas": cas,              # "1211441-98-3"
                "reading_ugm3": reading_ugm3,
                "context": "cdk4_6_second_two_nda_class_null_qtcf_bbw_herg_monaleesa7_novartis"
            }
        )
    return resp.json()
    # Glyphward returns: hd_category, cdk4_6_class_flag, cdk4_6_two_nda_class_null,
    #                    qtcf_black_box_warning, herg_kcnh2_off_target,
    #                    monaleesa7_premenopausal_os_benefit, first_novartis_cdk_null,
    #                    paloma_ribociclib_class_cross_null, h340_h350_h361_absent

if __name__ == "__main__":
    r = asyncio.run(scan_ribociclib("1211441-98-3", 0.00039))
    print(r)
    # {'hd_category': 1, 'cdk4_6_class_flag': True, 'cdk4_6_two_nda_class_null': True,
    #  'qtcf_black_box_warning': True, 'herg_kcnh2_off_target': True,
    #  'monaleesa7_premenopausal_os_benefit': True, 'first_novartis_cdk_null': True,
    #  'paloma_ribociclib_class_cross_null': True, 'h340_h350_h361_absent': True}